Two leading drug makers saw their growth up to 47 per cent in net profit for the year ended on June 30, 2021, compared to the same period of the previous year.
Beximco Pharmaceuticals has registered a 47 per cent growth in net profit while Square Pharmaceuticals posted a 14 per cent growth.
For fiscal year (FY) 2020-21, Beximco Pharmaceuticals reported a net profit of over Tk 4.94 billion, up from Tk 3.36 billion in the previous FY.
The company's EPS (earnings per share) stood at Tk 11.08 for FY 2020-21 as against Tk 7.54 in FY 2019-20.
The net asset value of Beximco Pharmaceuticals stood at Tk 82.28 for the year ended on June 30, 2021, as against Tk 79.78 for the same period of the previous year.
The company's board of directors has recommended a 35 per cent cash dividend for the year ended on June 30, 2021. In the previous fiscal, it declared 15 per cent cash and 10 per cent stock dividend.
On the other hand, the net profit of Square Pharmaceuticals stood at above Tk 14.74 billion for the year ended on June 30, 2021, registering a 14 per cent rise from the previous fiscal year's net profit of over Tk 12.96 billion.
The company reported its EPS of Tk 16.63 for the year ended on June 30, 2021 as against Tk 14.62 for the same period of the previous fiscal year.
It reported its net asset value per share of Tk 92.75 for FY 2020-21 as against Tk 78.86 for the previous FY.
The company's board of directors has recommended a 60 per cent cash dividend for the year ended on June 30, 2021.
The company maintained a continuity of good dividend disbursed in recent years.
It disbursed 47 per cent cash and 5.0 per cent stock dividend for the year ended on June 30, 2020.
The board of directors of Square Pharmaceuticals has also approved Tk 3.0 billion for BMRE, capital machinery and land for future expansion.
Beximco Pharmaceuticals, presently an 'A' category company, was listed with the stock exchange in 1986.
The company's sponsor-directors hold 30.18 per cent shares, institutions 20.05 per cent, foreigners 30.18 per cent and general shareholders 19.59 per cent as on September 30, 2021.
The share price of Beximco Pharmaceuticals closed at Tk 229.60 each on Thursday.
Square Pharmaceuticals, also an 'A' category company, was listed with the stock exchanges in 1995.
The company's sponsor-directors hold 34.57 per cent shares, institutions 13.64 per cent, foreigners 14.51 per cent and general shareholders 37.28 per cent as on September 30, 2021.
The company's share price closed at Tk 233.80 each on Thursday.
mufazzal.fe@gmail.com